Stonebridge Capital Advisors LLC Acquires 8,003 Shares of Eli Lilly and Company $LLY

Stonebridge Capital Advisors LLC raised its stake in Eli Lilly and Company (NYSE:LLY) by 318.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,519 shares of the company’s stock after buying an additional 8,003 shares during the period. Stonebridge Capital Advisors LLC’s holdings in Eli Lilly and Company were worth $8,026,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently modified their holdings of LLY. Brighton Jones LLC raised its stake in Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after buying an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC increased its stake in Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after purchasing an additional 40 shares in the last quarter. OneAscent Wealth Management LLC lifted its stake in shares of Eli Lilly and Company by 32.0% during the second quarter. OneAscent Wealth Management LLC now owns 359 shares of the company’s stock worth $280,000 after buying an additional 87 shares during the period. Sequoia Financial Advisors LLC grew its stake in Eli Lilly and Company by 19.0% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 140,201 shares of the company’s stock valued at $109,291,000 after purchasing an additional 22,410 shares during the last quarter. Finally, Schnieders Capital Management LLC. boosted its position in Eli Lilly and Company by 16.7% in the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after buying an additional 1,141 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 0.4%

Shares of NYSE LLY opened at $1,004.12 on Thursday. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. The business’s 50 day moving average is $1,049.25 and its two-hundred day moving average is $936.91. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95. The firm has a market cap of $947.25 billion, a price-to-earnings ratio of 43.75, a PEG ratio of 1.17 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. The business had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The company’s revenue was up 42.6% on a year-over-year basis. During the same period in the previous year, the firm posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. Eli Lilly and Company’s payout ratio is currently 30.15%.

Wall Street Analyst Weigh In

Several equities research analysts have commented on LLY shares. Deutsche Bank Aktiengesellschaft upped their price target on shares of Eli Lilly and Company from $1,200.00 to $1,285.00 and gave the company a “buy” rating in a report on Monday, February 9th. TD Cowen boosted their price target on shares of Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a “buy” rating in a report on Thursday, January 29th. National Bank Financial set a $1,286.00 target price on Eli Lilly and Company in a research report on Monday, December 1st. Leerink Partners increased their target price on shares of Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the company an “outperform” rating in a research report on Thursday, February 5th. Finally, Truist Financial reissued a “buy” rating on shares of Eli Lilly and Company in a research note on Monday, February 23rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $1,229.59.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly launched the “Lilly Employer Connect” platform to help U.S. employers expand coverage for obesity medicines, offering flexible benefit designs and partnerships with 15+ independent program administrators; company is also offering a Zepbound (tirzepatide) KwikPen single‑patient supply at $449 across doses via the program — this aims to widen patient access while controlling employer costs, supporting uptake and recurring revenue. Lilly Employer Connect platform launches (PRNewswire)
• Positive Sentiment: Lilly confirmed an oral GLP‑1 weight‑loss drug is under evaluation by Australia’s TGA — approval of an oral formulation would broaden prescriber options and patient adoption versus injectables, potentially expanding market share in the fast‑growing obesity/GLP‑1 category. Eli Lilly confirms oral GLP‑1 being evaluated by TGA (AFR)
• Positive Sentiment: EMA issued a positive opinion for Olumiant in alopecia areata — regulatory support broadens Lilly’s immunology portfolio outside metabolic drugs, adding a new commercial avenue and diversification of growth drivers. EMA’s Positive Olumiant Alopecia Opinion (Yahoo Finance)
• Positive Sentiment: Lilly advanced remternetug testing in China and progressed a new oral diabetes candidate in China — clinical expansion in large markets strengthens long‑term neuroscience and diabetes pipelines, important for growth beyond current GLP‑1 momentum. Remternetug testing advances in China (TipRanks)
• Neutral Sentiment: Ventyx Biosciences shareholders approved a merger with Lilly — strategic bolt‑on to strengthen specific capabilities; impact depends on integration and commercialization execution. Ventyx merger approval (TipRanks)
• Neutral Sentiment: Analyst/features pieces (Zacks, 247WallSt, Motley Fool) highlight Lilly as a momentum stock amid GLP‑1 strength but debate whether investors should prefer other long‑term picks — these stories can drive short‑term interest but add little fundamental news. Zacks: Why LLY is a momentum stock

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.